TWi Biotechnology, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2010)

Organization Overview

First Clinical Trial
2011
NCT01276106
First Marketed Drug
2010
atenolol (tenormin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

TWi Biotechnology, Inc. | TWI PHARMS | TWI PHARMS INC